|
|
|
| Moxifloxacin on Lung Function Oxygen Metabolism and Serum CRP CK LDH NBC Levels of COPD Patients with Respiratory Failure |
| MA Feifei, SHI Liang |
| Shenyang North Theater General Hospital, Liaoning Shenyang 110000, China |
|
|
|
|
Abstract Objective: To explore the effects of moxifloxacin in the treatment of chronic obstructive pulmonary disease (COPD) patients with respiratory failure on lung function, oxygen metabolism, serum C-reactive protein (CRP), creatine kinase (CK), lactate dehydrogenase (LDH), and neutrophils (NBC) level. Methods: 62 COPD patients with respiratory failure admitted between March 2018 and March 2020 were selected as the research objects, and were simply randomly divided into observation group and control group, with 31 cases in each group, using a random number table. Patients in the two groups received conventional treatment. Patients in the control group were treated with aerosol inhalation of salbutamol sulfate, and patients in the observation group were treated with aerosol inhalation of moxifloxacin. The differences in lung function, oxygen metabolism indexes, serum CRP, CK, LDH, and NBC levels before and after treatment were compared between the two groups of patients and the clinical efficacy. Results: Before treatment, there was no significant difference in the levels of FVC, FEV1, FEV1/FVC, CaO2, VO2 Max, ERO2, serum CRP, CK, LDH, and NBC between the two groups of patients (P>0.05); The levels of FVC, FEV1, FEV1/FVC, and CaO2 were higher than before treatment, and the increase in the observation group was greater, while the VO2 Max, ERO2, serum CRP, CK, LDH, and NBC levels of the two groups of patients were lower than before treatment. The degree of reduction in the observation group was greater, and the difference was statistically significant (P<0.05). The difference in efficacy between the two groups of patients was statistically significant (P<0.05). The total effective rate of clinical efficacy in the observation group was 96.77%, which was significantly higher than that of the control group (80.65%). The difference was statistically significant (P<0.05) . Conclusion: Moxifloxacin has a significant effect in the treatment of COPD patients complicated with respiratory failure, which can effectively improve patients' lung function, oxygen metabolism, and improve patients' serum CRP, CK, LDH, and NBC levels. It is worthy of clinical promotion.
|
|
|
|
|
|
[1] 周小敏,王成存,赵展庆,等.COPD合并呼吸衰竭患者血清HEPCIDIN表达及与预后评估关系[J].河北医学,2019,25(9):1426~1431.
[2] Passi M,Shahid S,Chockalingam S,et al.Conventional and nanotechnology based approaches to combat chronic obstructive pulmonary disease:implications for chronic airway diseases[J].Int Nanomedicine,2020,15:3803~3826.
[3] 贾晓佳.莫西沙星溶液雾化吸入治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的效果及对机体相关指标的影响[J].中国医药,2019,14(7):984~987.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255~264.
[5] 葛均波,徐永健.内科学[M].第8版.人民卫生出版社,2013.
[6] 曲宝亮,穆怀博,孟爱霞,等.慢性阻塞性肺疾病患者应用莫西沙星治疗的疗效及预后分析[J].湖南师范大学学报(医学版),2019,16(2):130~132.
[7] Gadre SK,Duggal A,Mireles CE,et al.Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD)[J].Medicine,2018,97(17):e0487.
[8] 熊天增.莫西沙星治疗慢性阻塞性肺疾病急性加重期的疗效及对细菌清除率的影响[J].四川医学,2018,39(5):582~585.
[9] 年英,吕秀云.美罗培南联合莫西沙星对慢性阻塞性肺疾病并发感染性肺炎患者的影响[J].实用心脑肺血管病杂志,2019,27(3):87~90.
[10] Lin TL,Chen WW,Ding ZR,et al.Correlations between serum amyloid A,C-reactive protein and clinical indices of patients with acutely exacerbated chronic obstructive pulmonary disease[J].Clin Lab Anal,2019,33(4):e22831.
[11] 袁璟,王军蒙,蔡云,等.心肌缺血损伤与炎性反应及针刺的抗炎作用[J].针刺研究,2019,44(4):302~306. |
|
|
|
2021, Vol. 27 
